Develops protein-based, antigen-specific immune tolerogens as drugs to cure autoimmune diseases by specifically targeting the disease-causing immune response. Focuses on patients with autoimmune orphan diseases, with lead programs in myasthenia gravis and ANCA vasculitis aiming for long-acting or curative therapies.